Digestion
Cure8 research brief
Why This Matters
Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.
This study describes real‑world use of upadacitinib started during admission and reports lower observed colectomy rates than some historical rescue treatments, which may be of interest to patients and clinicians considering options when IV steroids are insufficient.
Who Should Pay Attention
Adult patients hospitalized with acute severe ulcerative colitis, clinicians who manage inpatient IBD care, patients on or considering advanced therapies (JAK inhibitors/biologics), and researchers studying rescue strategies for ASUC.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a small, retrospective series from Mayo Clinic sites describing real-world use of upadacitinib started during hospitalization for ASUC. It suggests lower observed colectomy rates than historical reports of infliximab or cyclosporine rescue, but the study is descriptive and not randomized.
Because the data come from a limited cohort (n=23) with heterogeneous prior therapies and some patients already on low‑dose UPA, the results should be interpreted cautiously. The study reports feasibility and short-term surgical outcomes but does not establish comparative effectiveness or long-term safety. Future prospective, controlled studies are needed.
If you are a patient considering or currently on upadacitinib, discuss with your IBD team whether inpatient initiation is appropriate for your situation; this study alone does not change clinical guidelines.
Keep In Mind
This is a small, retrospective, descriptive cohort from a single healthcare system; it is not a randomized trial. Some patients had prior exposure to multiple advanced therapies and a few were already on low‑dose upadacitinib, which may affect outcomes. The abstract provides an initial signal but does not replace larger prospective studies or guideline recommendations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDigestion
AuthorsFares Jamal, Alejandro J Gonzalez, Sandra Elmasry +2 more
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 29, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...